| Segment | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Licensing, royalties, and other | $42.98M | $29.06M | $44.98M | $228.52M | $57M | $107.94M | $97.31M | $37.84M |
| Cost reimbursements | — | — | $11.27M | $6.48M | $45.83M | $28.05M | $27.72M | $22.6M |
| Upfront fee amortization | — | — | $19.91M | $12.27M | -$1.08M | $12.82M | $12.11M | $8.73M |
| Milestones amortization | — | — | $9.14M | $5.67M | -$645K | $5.87M | $5.55M | $3.76M |
| Royalties | $4.56M | -$4.56M | $0 | $5M | $4.2M | $7.8M | $3.52M | $700K |
| Support services | $354K | $583K | $0 | $278K | $272K | $250K | $100K | $265K |
| Milestones | — | — | — | $175M | $4.72M | $50M | — | $0 |
| Nuvaxovid sales | $38.21M | $49.77M | $608.03M | — | — | — | — | — |
| Supply sales | $3.32M | $9.49M | $13.65M | — | — | — | — | — |
| Upfront fee | — | — | — | $18.5M | $0 | — | — | $0 |
| Total | $84.51M | $88.31M | $666.66M | $239.24M | $70.45M | $147.14M | $139.51M | $56.7M |